AbbVie ABBV announced that it has entered into a collaboration and option-to-license agreement with the San Diego-based private biotech Neomorph to develop molecular glue degraders for multiple targets across oncology and immunology.
Molecule glue degraders are a novel class of small molecules designed to selectively degrade proteins that drive disease. AbbVie will utilize Neomorph’s proprietary discovery platform to target proteins that are considered ‘undruggable’.
Per the terms of the deal, Neomorph will receive an undisclosed amount as an upfront payment from AbbVie. The San Diego company will also be eligible to receive up to $1.64 billion in aggregate option fees and milestones, along with tiered royalties based on net sales.
Founded in 2020, Neomorph has been garnering interest from big pharma for its discovery platform. Last year, it signed separate multi-billion dollar partnerships with big-wigs Biogen BIIB and Novo Nordisk NVO. While the NVO deal (worth $1.46 billion) targets cardiometabolic and rare diseases, the $1.45 billion deal with BIIB focuses on immunology and neurology, including Alzheimer's disease.
ABBV Stock Performance
In the past year, shares of AbbVie have gained 4% against the industry’s 4% decline.
Image Source: Zacks Investment Research
AbbVie Continues Acquisition Spree
AbbVie has been on an acquisition spree in the past couple of years, strengthening its pipeline. It has signed several M&A deals in the immunology space, its core area, and some early-stage deals in oncology and neuroscience areas.
Last year, ABBV acquired smaller biotechs like Landos Biopharma and Celsius Therapeutics that make novel drugs for treating inflammatory bowel disease (IBD), which has become quite a popular space of late. It also signed a license agreement with China’s FutureGen to develop a next-generation anti-TL1A antibody for IBD.
Earlier this week, ABBV completed the acquisition of immunology drugmaker Nimble Therapeutics. With this acquisition, it added Nimble’s innovative oral peptide-based therapies, including a novel IL23R inhibitor (also the lead asset) currently in preclinical development, for the treatment of psoriasis.
Last week, ABBV signed an option-to-license agreement with Hong Kong-based Simcere to develop a novel trispecific antibody candidate in multiple myeloma indication.
Among some other recent deals, the company acquired private neuroscience drugmaker biotech Aliada Therapeutics, signed a collaboration and licensing agreement with EvolveImmune Therapeutics to develop next-generation cancer biotherapeutics and expanded its existing neuroscience collaboration with Gedeon Richter.
ABBV’s Zacks Rank
AbbVie currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Zacks Names #1 Semiconductor Stock
It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom.
With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028.
See This Stock Now for Free >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Biogen Inc. (BIIB): Free Stock Analysis Report
Novo Nordisk A/S (NVO): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
/Super%20Micro%20Computer%20Inc%20logo%20on%20building-by%20Poetra_RH%20via%20Shutterstock.jpg)
